

WEST Search History

DATE: Monday, October 03, 2005

Hide?	<u>Set Name</u>	<u>Query</u>	<u>Hit Count</u>
		<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=AND</i>	
<input type="checkbox"/>	L5	13 and 13-28	71
<input type="checkbox"/>	L4	L3 and 5688651	22
<input type="checkbox"/>	L3	L2 and aggregat\$8	520
<input type="checkbox"/>	L2	L1 and amyloid\$8	745
<input type="checkbox"/>	L1	266 same antibod\$6	7302

END OF SEARCH HISTORY

STIC-ILL

18655205

565199

From:
Sent:
To:
Subject:

Turner, Sharon
Monday, November 28, 2005 2:25 PM
STIC-ILL
10788666

NPL _____ Adonis _____
MIC _____ BioTech _____ MAIN _____
NO ☒ Vol NO _____ NOS _____
Ck Cite _____ Dupl Request _____
Call # _____

11/28/05 D.C.

Please provide

Kayed et al., J. Mol. Biol., 287(4):781-96, 1999

Chen et al., Progress in Br. Res., 117:327-34, 1998

Lemere et al., Soc. for Neurosci. Abstr., vol 25 pt. 1, Abstr. 519.6, 296
10/23-10/28, 1999

COMPLETED

Sharon L. Turner, Ph.D.
USPTO Biotechnology 1649
Remsen 4A19
Mailroom 4C70
(571) 272-0894

STIC-ILL

From: Turner, Sharon
Sent: Monday, November 28, 2005 2:25 PM
To: STIC-ILL
Subject: 10788666

NPL Adonis
MIC BioTech ☒ MAIN
NO Vol NO NOS
Ck Cite Dupl Request
Call # Q.P.351.5.56916
11/28/05 D.C.

Please provide

Kayed et al., J. Mol. Biol., 287(4):781-96, 1999

Chen et al., Progress in Br. Res., 117:327-34, 1998

Lemere et al., Soc. for Neurosci. Abstr., vol 25 pt. 1, Abstr. 519.6, 29th Ann. Mtg.
10/23-10/28, 1999

Sharon L. Turner, Ph.D.
USPTO Biotechnology 1649
Remsen 4A19
Mailroom 4C70
(571) 272-0894

STIC-ILL

From: Turner, Sharon
Sent: Monday, November 28, 2005 2:25 PM
To: STIC-ILL
Subject: 10788666

NPI ☒ Adonis ☒
MIC ☐ BioTech ☒ MAIN ☐
NO ☐ Vol NO ☐ NOS ☐
Ck Cite ☐ Dupl Request ☐
Call # QH301573

11/28/05 D.C.

Please provide

Kayed et al., J. Mol. Biol., 287(4):781-96, 1999

Chen et al., Progress in Br. Res., 117:327-34, 1998

Lemere et al., Soc. for Neurosci. Abstr., vol 25 pt. 1, Abstr. 519.6, 29th Ann. Mtg.
10/23-10/28, 1999

Sharon L. Turner, Ph.D.
USPTO Biotechnology 1649
Remsen 4A19
Mailroom 4C70
(571) 272-0894

ANSWER 4 OF 22 MEDLINE on STN
 AN 2004003007 MEDLINE
 DN PubMed ID: 14698294
 TI Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy.
 AU Legleiter Justin; Czilli Dan L; Gitter Bruce; DeMattos Ronald B; Holtzman David M; Kowalewski Tomasz
 CS Department of Chemistry, Carnegie Mellon University, 4400 Fifth Avenue, Pittsburgh, PA 15213, USA.
 NC AG05681 (NIA)
 AG20222 (NIA)
 SO Journal of molecular biology, (2004 Jan 23) 335 (4) 997-1006.
 Journal code: 2985088R. ISSN: 0022-2836.
 CY England: United Kingdom
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals
 EM 200402
 ED Entered STN: 20040106
 Last Updated on STN: 20040211
 Entered Medline: 20040210
 AB Extensive data suggest that the conversion of the amyloid-beta (Abeta) peptide from soluble to insoluble forms is a key factor in the pathogenesis of Alzheimer's disease (AD). In recent years, atomic force microscopy (AFM) has provided useful insights into the physicochemical processes involving Abeta morphology, and it can now be used to explore factors that either inhibit or promote fibrillogenesis. We used ex situ AFM to explore the impact of anti-Abeta antibodies directed against different domains of Abeta on fibril formation. For the AFM studies, two monoclonal antibodies (m3D6 and m266.2) were incubated in solution with Abeta(1-42) with a molar ratio of 1:10 (antibody to Abeta) over several days. Fibril formation was analyzed quantitatively by determining the number of fibrils per microm(2) and by aggregate size analysis. m3D6, which is directed against an N-terminal domain of Abeta (amino acid residues 1-5) slowed down fibril formation. However, m266.2, which is directed against the central domain of Abeta (amino acid residues 13-28) appeared to completely prevent the formation of fibrils over the course of the experiment. Inhibition of fibril formation by both antibodies was also confirmed by thioflavin-T (ThT) fluorescence experiments carried out with Abeta(1-40) incubated for five days. However, unlike AFM results, ThT did not differentiate between the samples incubated with m3D6 versus m266.2. These results indicate that AFM can be not only reliably used to study the effect of different molecules on Abeta aggregation, but that it can provide additional information such as the role of epitope specificity of antibodies as potential inhibitors of fibril formation.

Anti-aggregating.

ANSWER 15 OF 22 MEDLINE on STN
AN 2001419655 MEDLINE
DN PubMed ID: 11438712
TI Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease.
CM Comment in: Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):8931-2. PubMed ID: 11481462
AU DeMattos R B; Bales K R; Cummins D J; Dodart J C; Paul S M; Holtzman D M
CS The Center for the Study of Nervous System Injury, Washington University School of Medicine, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.
SO Proceedings of the National Academy of Sciences of the United States of America, (2001 Jul 17) 98 (15) 8850-5. Electronic Publication: 2001-07-03.
Journal code: 7505876. ISSN: 0027-8424.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200108
ED Entered STN: 20010903
Last Updated on STN: 20030105
Entered Medline: 20010830
AB Active immunization with the **amyloid** beta (A beta) peptide has been shown to decrease brain A beta deposition in transgenic mouse models of Alzheimer's disease and certain peripherally administered anti-A beta antibodies were shown to mimic this effect. In exploring factors that alter A beta metabolism and clearance, we found that a monoclonal antibody (**m266**) directed against the central domain of A beta was able to bind and completely sequester plasma A beta. Peripheral administration of **m266** to PDAPP transgenic mice, in which A beta is generated specifically within the central nervous system (CNS), results in a rapid 1,000-fold increase in plasma A beta, due, in part, to a change in A beta equilibrium between the CNS and plasma. Although peripheral administration of **m266** to PDAPP mice markedly reduces A beta deposition, m266 did not bind to A beta deposits in the brain. Thus, **m266** appears to reduce brain A beta burden by altering CNS and plasma A beta clearance.